Nrf2调控狼疮巨噬细胞干扰素受体表达与极化
该研究探讨了狼疮中巨噬细胞I型干扰素受体(IFNAR)表达的调控机制。研究发现,转录因子Nrf2在促分解非经典巨噬细胞(NCM)中表达增高,Nrf2激活剂CDDO-Im可减少经典巨噬细胞(CM)、降低Ifnar1和干扰素刺激基因(ISG)表达并缓解氧化应激,而Nrf2抑制剂brusatol作用相反;Nrf2敲除小鼠Ifnar1和ISG表达更高;SLE患者亦显示Nrf2活性降低。结论提示Nrf2激活有利于狼疮慢性炎症的消退。
要点
- Nrf2激活剂CDDO-Im减少CM并促进促分解NCM发育。
- CDDO-Im降低巨噬细胞Ifnar1和ISG表达,缓解氧化应激。
- SLE患者血液细胞显示Nrf2活性降低。
核心结论
- Nrf2激活有利于狼疮慢性炎症的消退。
- Nrf2激活剂可重极化巨噬细胞并减少干扰素特征,可能值得考虑用于治疗狼疮。
研究设计与样本
- 对经pristane(发生狼疮)或矿物油(非狼疮对照)处理小鼠的纯化CM和NCM进行基因表达谱分析。
- 在Nrf2激活剂/抑制剂处理小鼠及Nrf2缺陷小鼠中检查巨噬细胞分化和IFNAR表达。
- 评估SLE患者血细胞的Nrf2活性。
- 显著性差异采用Student t检验判定。
主要发现
- RNA测序显示,与pristane处理小鼠相比,矿物油处理小鼠的NCM中Nrf2调控基因表达增加;NCM与CM相比亦增高。
- CDDO-Im减少CM(P < 0.0001),促进促分解NCM发育(P = 0.06)。
- brusatol增加CM(P < 0.05),减少NCM(P < 0.001)。
- CDDO-Im降低巨噬细胞Ifnar1(P < 0.001)和ISG表达,并缓解氧化应激(P < 0.05);brusatol作用相反(P < 0.01)。
- Nrf2敲除小鼠Ifnar1和ISG表达水平高于对照(P < 0.05);SLE患者显示Nrf2活性低的证据。
临床怎么用
- Nrf2激活剂可能通过重极化巨噬细胞、降低IFNAR信号,为狼疮治疗提供新思路。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Pristane-induced lupus is associated with nonresolving inflammation and deficiency of proresolving macrophages. Proresolving nonclassic macrophages (NCMs) are less responsive to type I interferon (IFN) than classic macrophages (CMs; which are proinflammatory), reflecting their relative expression levels of the type I IFN receptor (IFNAR). This study was undertaken to investigate the regulation of IFNAR expression in macrophages. METHODS: We carried out gene expression profiling of purified CMs and NCMs from mice treated with pristane (which develop lupus) or mineral oil (non-lupus controls). Macrophage differentiation and IFNAR expression were examined in mice treated with NF-E2-related factor 2 (Nrf2) activators and inhibitors and in Nrf2-deficient mice. Nrf2 activity was also assessed in blood cells from patients with systemic lupus erythematosus (SLE). Significant differences were determined by Student's t-test. RESULTS: RNA sequencing revealed increased expression of genes regulated by the transcription factor Nrf2 in NCMs from mineral oil-treated versus pristane-treated mice and in NCMs versus CMs. The Nrf2 activator CDDO-imidazole (CDDO-Im) decreased CMs (P < 0.0001) and promoted the development of proresolving NCMs (P = 0.06), whereas the Nrf2 inhibitor brusatol increased CMs (P < 0.05) and decreased NCMs (P < 0.001). CDDO-Im decreased Ifnar1 (P < 0.001) and IFN-stimulated gene (ISG) expression in macrophages and alleviated oxidative stress (P < 0.05), whereas brusatol had the opposite effect (P < 0.01). Moreover, Ifnar1 and ISG expression levels were higher in Nrf2-knockout mice than controls (P < 0.05). As seen in mice with lupus, SLE patients showed evidence of low Nrf2 activity. CONCLUSION: Our findings indicate that Nrf2 activation favors the resolution of chronic inflammation in lupus. Since autoantibody production and lupus nephritis depend on IFNAR signaling, the ability of Nrf2 activators to repolarize macrophages and reduce the INF signature suggests that these agents may warrant consideration for treating lupus.
引用
- Han S, Zhuang H, Lee PY, et al. NF-E2-Related Factor 2 Regulates Interferon Receptor Expression and Alters Macrophage Polarization in Lupus. Arthritis Rheumatol. 2020. PMID: 32500632. doi:10.1002/art.41383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。